1 December 2022
Chemotherapy with or without algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer.
Hewitt, DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL et al.
Ann Surg 2022; 275: 45-53.
In this study that included 303 patients, the addition of neoadjuvant immunotherapy did not improve progression-free survival (12. versus 13.4 months in controls) or overall survival (14.3 versus 14.9 months, respectively).
Comment: disappointing negative result.
1 February 2022Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.